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Previews
designed to remove amyloid pathology. In demonstra-Clearing Tau Pathology with A
ting the removal of early tau pathology with reagentsImmunotherapy—Reversible directed at the clearance of amyloid (A antibodies or
-secretase inhibitors), Oddo et al. (2004) provide theand Irreversible Stages Revealed
most complete confirmation of the amyloid cascade hy-
pothesis to date. This study also shows that after A
antibody treatment, amyloid and early tau pathologies
The report by Oddo and colleagues in this issue of are first cleared from the brain and then reemerge ac-
Neuron demonstrates for the first time that clearance cording to a specific hierarchy (within 45 days); this
of amyloid also results in the removal of early-stage result provides further support for the hypothesis that
tau pathology in mice that develop both amyloid A species initiate tau pathogenesis in this model. Im-
plaques and neurofibrillary tangles (NFT), the two hall- portantly, however, while early-stage somatodendritic
mark lesions of Alzheimer’s disease (AD). This result accumulations of tau are apparently reversed by A
immunotherapy, through a proteasome-dependentsupports a primary role for A in AD etiology.
mechanism, later-stage hyperphosphorylated tau le-
sions that resemble human NFT are not significantlyAlzheimer’s disease (AD) is characterized neuropatho-
reduced by the same treatment.logically by the presence of extracellular amyloid plaques,
This result implies that initial somatodendritic accu-composed of aggregated A peptide, and intraneuronal
mulations of tau are modified during pathogenesis toneurofibrillary tangles (NFT), which are filamentous le-
the point where they can no longer be removed aftersions made up of hyperphosphorylated forms of the
A antibody or -secretase inhibitor-driven clearancemicrotubule-associated protein tau. While the composi-
of amyloid. Clearly, determining the precise nature oftion of these two lesions has been known for almost 20
this tau lesion modification will have important mecha-years, the mechanistic relationship between A and tau
nistic and potentially therapeutic implications. The de-in disease etiology has remained a source of consider-
velopment of NFT, in both human AD and in mouseable debate. The observation that early-onset autoso-
models of tauopathy, initially involves the redistributionmal dominant AD is caused by mutations in three genes
of tau from microtubules within axons to the somatoden-(the amyloid precursor protein [APP], Presenilin-1, and
dritic compartment of the neuron. This process is inevi-Presenilin-2 [PS-1/2]), all of which increase the produc-
tably associated with the progressive hyperphosphory-tion of A42, the most amyloidogenic form of A, led to
lation of tau at multiple sites within the protein. Multiplethe so-called amyloid cascade hypothesis (Hardy and
neuropathological studies have further shown that theseSelkoe, 2002). This hypothesis proposed that the accu-
phosphorylation events appear to occur in a hierarchicalmulation of toxic aggregated A species is responsible
manner in which some sites are consistently phosphory-
for inducing the other neuropathological features of AD,
lated before others during pathogenesis (Augustinack
including the formation of NFT (Hardy and Selkoe, 2002).
et al., 2002). While the significance of hyperphosphoryla-
The current paper by Oddo and colleagues (2004 [this tion in tangle development remains uncertain, hyper-
issue of Neuron]) is of significance because this research phosphorylated tau is unable to bind microtubules, and
demonstrates for the first time that A immunotherapy in addition, enhancing tau phosphorylation by increas-
or a -secretase inhibitor that blocks A production is ing kinase activity accelerates NFT formation and neuro-
able to remove not only amyloid pathology but also degeneration in transgenic animal models (Noble et al.,
early-stage tau lesions from the brains of triple trans- 2003). Oddo et al. (2004) speculate that the key modifica-
genic mice (3xTg-AD) that develop both amyloid plaques tion in producing irreversible (by A clearance) tau le-
and NFT (Oddo et al., 2003). These findings provide sions in 3xTg-AD mice is this process of hyperphosphor-
compelling evidence that pathological A species are ylation, since the early somatodendritic accumulations
able to induce the progressive accumulation of tau in of tau that are cleared by A antibody treatment (at 12
the somatodendritic compartment of neurons, eventu- months in heterozygous and 6 months in homozygous
ally resulting in NFT formation. This study thus extends 3xTg-AD mice) do not show evidence of pathological
earlier work in transgenic models, published in 2001, phosphorylation. This is demonstrated by the fact that
which previously suggested that an interaction occurs this early pathology is not detected by AT8, an antibody
between the A and tau pathologies in AD (Gotz et al., that detects a pathological phosphorylation event (at
2001; Lewis et al., 2001). In these earlier experiments, residues serine 202/threonine 205). In contrast, the later
TAPP mice, which express both mutant APP and mutant irreversible tau pathology (in 12-month-old homozygous
tauP301L transgenes, were shown to develop enhanced 3xTg-AD mice) is positive for both AT8 and AT180 (an-
corticolimbic NFT pathology compared to single trans- other phospho-dependent tau antibody). Based on this
genic littermates expressing tauP301L alone (Lewis et al., data, the hypothesis that tau hyperphosphorylation is
2001); similarly, mutant tauP301L mice that received injec- responsible, at least in part, for producing irreversible
tions of filamentous A also developed increased NFT tau lesions is reasonable; however, there are other po-
numbers in the amygdala (Gotz et al., 2001). However, tential explanations. In particular, the early somatoden-
neither of these earlier reports described the prevention dritic tau accumulations that are cleared in these studies
are unlikely to contain a significant amount of aggre-or clearance of tau lesions with antibodies or drugs
Neuron
294
gated filamentous tau, whereas the later-stage irrevers- spread of NFT pathology to other brain regions. Cessa-
ible lesions, which are also detected by the Gallyas sil- tion or slowing of cognitive decline will likely depend on
ver stain, will almost certainly be composed largely of how many neurons in different AD-affected brain regions
tau filaments. Therefore, an alternative explanation for have already developed irreversible tau lesions at the
the shift to tau pathology that cannot be reversed by time of treatment and whether these lesions continue
A immunotherapy is the ongoing process of tau aggre- to accumulate tau and cause neurodegeneration after
gation or the attainment of a particular aggregated A-based therapy. The results from trials in AD patients
conformation. Indeed, the hyperphosphorylated state of treated with A-based therapies will clearly be critical
human and mouse NFT may simply reflect the accumula- in determining the degree to which these strategies are
tion of filamentous tau, since aggregated tau remains a able to halt disease progression. Preliminary clinical re-
kinase substrate (Schneider et al., 1999), while phospha- sults in a subset of patients treated with the Elan A
tase enzymes may be unable to remove phosphate moi- vaccine (AN1792) do suggest a slowing of cognitive de-
eties from these structures, resulting in the observed cline (Hock et al., 2003), but analysis of the entire
hyperphosphorylation. Regardless of the explanation for multicenter set of AN1792-treated patients will be re-
the inability of A antibodies to remove later-stage tau quired to determine the extent of this effect.
lesions in 3xTg-AD mice, further biochemical studies to In conclusion, the paper by Oddo et al. (2004) provides
determine the critical modifications during tau patho- compelling evidence that the accumulation of A is able
genesis will be important for understanding the basis to induce the development of tau pathology, consistent
for these current findings. with the amyloid cascade hypothesis. In addition, this
The potential implications of this research for AD ther- study suggests that the proteasome is involved in the
apeutic strategies are clearly complex. The results from removal of early-stage tau pathology by A antibodies
the 3xTg-AD mice suggest that clearance of aggregated or a -secretase inhibitor. Perhaps most significantly,
A from the brains of human patients should prevent the current study in the 3xTg-AD mouse begins to define
development of NFT pathology provided that this is per- tau pathological stages that are likely to be reversible
formed sufficiently early in the pathogenic cascade. or irreversible by A-based therapeutic strategies and
However, once NFT lesions have formed, these will not therefore suggests that a multitarget approach to ther-
be removed by A-based therapies. These results are apy may be the most effective strategy in the treatment
consistent with neuropathological results from patients of clinical AD.
who received A immunotherapy (AN1792) as part of
the Elan clinical trial that was halted in 2002 (Nicoll et Michael Hutton and Eileen McGowan
al., 2003; Schenk et al., 1999). In each case, the brains Department of Neuroscience
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